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Systemic hereditary amyloidoses are autosomal dominant diseases associated with mutations in genes encoding ten different
proteins.The clinical phenotype has implications on therapeutic approach, but it is commonly variable and largely dependent on the
type of mutation. Except for rare cases involving gelsolin or transthyretin, patients are heterozygous for the amyloidogenic variants.
Here we describe the first patient identified worldwide as homozygous for a nephropathic amyloidosis, involving the fibrinogen
variant associated with the fibrinogen alpha-chain E526V (p.Glu545Val) mutation. In 1989, a 44-year-old woman presented with
hypertension, hepatosplenomegaly, nephrotic syndrome, and renal failure. She started hemodialysis in 1990 and 6 years later
underwent isolated kidney transplantation from a deceased donor. Graft function and clinical status were unremarkable for 16
years, despite progressively increased left ventricular mass on echocardiography. In 2012, 4 months before death, she deteriorated
rapidly with severe heart failure, precipitated by Clostridium difficile colitis and urosepsis. Affected family members developed
nephropathy, on average, nearly three decades later, which may be explained by the gene dosage effects on the phenotype of E526V
(p.Glu545Val) fibrinogen A alpha-chain amyloidosis.
1. Introduction
Hereditary fibrinogen A alpha-chain (AFib) amyloidosis is
a systemic amyloid disease first characterized in 1993 in
a Peruvian kindred [1–4]. It presents with proteinuria and
features a progressive decline in kidney function to end
stage renal failure (ESRF) within 5 years of diagnosis [3].
Nonetheless, there is a wide variability in disease onset,
systemic involvement, and penetrance. Renal replacement
therapy and transplantation are currently the mainstay of
therapy. However, because the liver is the source of the
amyloidogenic variant fibrinogen and there is no evidence
that WT fibrinogen can be amyloidogenic, the only curative
treatment is liver transplantation [5].
AFib amyloidosis appears to bemore commonworldwide
than previously recognized [6]. The R554L (p.Arg573Leu)
mutation was the first fibrinogen amyloidogenic variant
identified [1]. To date, thirteen amyloidogenic mutations
have been reported in the fibrinogen alpha-chain gene (FGA)
(http://amyloidosismutations.com/mut-afib.php), account-
ing for 8% of hereditary amyloidosis cases [7]. The most
commonmutant variant, E526V (p.Glu545Val), was identified
heterozygously in kindred members of Irish, British, Polish,
Portuguese, French, German, and Brazilian origin [2, 3, 8–
11]. Homozygosity has only been reported for hereditary
gelsolin and transthyretin amyloidosis (Table 1). In gelsolin
(AGel) amyloidosis, homozygotes have been reported to
show earlier onset and more severe clinical manifestations
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Table 1: Homozygous amyloidogenic variants reported in the literature.
Gene Proteinvariant
Sequence
variant (mRNA) Patients (𝑛)
Geographic
origin/ethnicity
Reported
phenotype Clinical course References
GSN Asp187Asn(p.Asp214Asn) c.640G>A 2 Finland
CN, CLD, SC,
CRF Severe nephropathy [12, 13]
TTR Val30Met(p.Val50Met) c.148G>A 19
Japan
Spain
Sweden
Turkey
PN, AN, VO,
GI, H, CN
Wide variability, from
asymptomatic carriers to slightly
more severe phenotypes with
higher incidence rate and earlier
onset than heterozygotes within
the same family
[14–19]
Leu58His
(p.Leu78His) c.233T>G 1 American/German PN, CMP More rapid course of disease [20]
Phe64Leu
(p.Phe84Leu) c.250T>C 1 Italy
PN, AN,
CMP More severe phenotype [21]
Val122Ile
(p.Val142Ile) c.424G>A 24 African/American CMP
Earlier age at onset and uncertain
penetrance, particularly with
respect to gender
[22, 23]
AN: autonomic neuropathy; CLD: corneal lattice dystrophy; CMP: cardiomyopathy; CN: cranial neuropathy; CRF: chronic renal failure; GI: gastrointestinal
symptoms; H: heart conduction disturbance; PN: peripheral polyneuropathy; SC: skin changes; VO: vitreous opacities.
than heterozygotes, explained by the lethal effects of the
mutant genes [12, 13]. However, in transthyretin (ATTR)
amyloidosis, the underlying molecular mechanisms are
largely unknown [14–23].
Here,wereport thefirsthomozygouspatientwithAFibE526V
(p.Glu545Val) amyloidosis, identified in 1989 and followed up
for 23 years. In this reported kindred, the comparison of the
clinical pictures of homozygote and heterozygotes provides
important information about the gene dosage effects on the
phenotype of AFib amyloidosis.
2. Case Report
2.1. Proband. A 44-year-old Caucasian northern Portuguese
woman who had suffered a single previous episode of upper
gastrointestinal hemorrhage presented with hypertension,
nephrotic syndrome, and renal failure in April 1989. Renal
biopsy 1 year later revealed abundant glomerular amyloid
deposition (Figure 1(a)); her serum creatinine was 4.0mg/dL
and proteinuria of 7.5 g/day was detected. In the absence
of any underlying inflammatory disease and unawareness
of family history, she was presumed to have immunoglob-
ulin light chain (AL) amyloidosis. However, there was no
evidence of cardiac amyloidosis, and neither a monoclonal
immunoglobulin nor a plasma cell disorder was identified.
She was treated with melphalan and corticosteroids but
progressed rapidly to ESRF and started hemodialysis in
December 1990. During hemodialysis, her functional status
remained good.
Successful isolated renal transplantation (RTx) was per-
formed in August 1996. At the time, she had no other
health problems. Physical examination revealed an enlarged
liver and spleen. There was no anemia or thrombocytope-
nia and liver function tests were normal. Blood coagula-
tion tests revealed low fibrinogen levels. Echocardiography
showed mild left ventricular hypertrophy without the typical
speckle appearance. Abdominal ultrasonography showed
hepatomegaly (17.5 cm), splenomegaly (14.5 cm), and bilat-
eral kidney atrophy. A neurophysiologic study of the lower
limbs found mild sensory peripheral neuropathy. Induction
and maintenance immunosuppression for transplantation
involved corticosteroids, cyclosporine, and azathioprine.
2.2. Histology and Immunohistochemistry. In 2001, we began
an extensive investigation to determine the patient’s amy-
loid type. Congo red staining of 6 𝜇m formalin fixed,
paraffin embedded section of the native kidney biopsy
confirmed abundant glomerular amyloid deposition and
absence of vascular and interstitial involvement. Immuno-
histochemical staining was performed on 2𝜇m sections of
amyloid-containing tissue using standard methods and a
rabbit/mouse, peroxidase/diaminobenzidine detection sys-
tem (REALEnVision: Dako, Glostrup, Denmark).mAbswere
directed against serum amyloid A (Dako), apolipoprotein A-
II (Abcam, Cambridge, UK), and transthyretin [24]; poly-
clonal antibodies were used for kappa light chain, lambda
light chain, fibrinogen A alpha-chain (FGA), transthyretin,
apolipoprotein A-I, and lysozyme (Dako). For light chains
and FGA, sections were treated with 10 𝜇g/mL proteinase K
for 10min at 37∘C and 10min at room temperature. Blocking
was performed with 5% bovine serum albumin/phosphate
buffered saline (BSA/PBS). Sections were incubated with
the antibodies for 2 h at room temperature and diluted in
1% BSA/PBS as follows: monoclonal anti-transthyretin, used
directly; polyclonal anti-transthyretin, 1 : 500; anti-serum
amyloidA, 1 : 100; anti-kappa light chain, 1 : 1000; anti-lambda
light chain, 1 : 2000; anti-FGA, 1 : 800; anti-lysozyme, 1 : 300;
anti-apolipoprotein A-I, 1 : 400; and anti-apolipoprotein A-
II, 1 : 600. Positive control tissues containing these amyloid
proteins were also stained during each run. The glomerular
amyloid deposits in the patient’s kidney biopsy reacted with
the anti-serum to FGA (Figure 1(a)).
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Figure 1: Homozygous E526V (p.Glu545Val) mutation in the fibrinogen alpha-chain gene (FGA) associated with fibrinogen A alpha-chain
amyloidosis in a Portuguese patient. (a) shows abundant glomerular amyloid deposition with typical apple-green birefringence (Congo red
staining under polarized light, ×200, left). Immunohistochemical staining was positive with polyclonal anti-fibrinogen antibodies, (×200,
right). (b) shows a partial sequence chromatogram of FGA. The mutation identified in the proband, which alters codon 545 (position 526 of
the mature protein) from GAG (glutamic acid) to GTG (valine), is depicted in a circle. (c) shows the pedigree of the affected kindred. The
homozygous patient (proband) is indicated by the arrow. The FGA p.Glu545Val mutation was identified heterozygously in family members
III7, III8, III10, IV3, IV4, IV5, and IV6 (indicated by half-solid symbols). Obligatory heterozygotes IV2 and IV7 (indicated by questionmarks)
did not perform genotyping because the former was abroad and the latter died at young age. Those with chronic renal failure who have not
undergone histologic or genetic testing are indicated by a black column inside the symbol. Familiars whose genetic tests were negative are
indicated by an N inside the symbol. Blank symbols indicate that tests have not been conducted and/or information is unavailable for these
individuals. Slashes denote deceased members.
2.3. Genetic Evaluation. DNA was extracted from peripheral
white blood cells obtained from whole blood. Exon 5 of the
FGA gene was amplified by the polymerase chain reaction
(PCR) with primers flanking the coding region (forward 5󸀠-
CCT TCT TCG ACA CTG CCT CAA CTG-3󸀠 and reverse
5󸀠-TCC TCT GTT GTA ACT CGT GCT-3󸀠), which ampli-
fied a fragment of 224 base pairs encompassing nucleotide
4827 to 5051. PCR products were analyzed by agarose gel
electrophoresis, purified, and sequenced with Big Dye Ter-
minator Cycle Sequencing Kit (Applied Biosystems, Foster
City, CA, USA) in an Applied Biosystems 3700 sequencer.
Sequences were analysed using ChromasPro. A homozygous
A to T transversion at nucleotide 4909 in FGA was detected;
this changes codon 526 of the mature protein (corresponding
to position 545 of the unprocessed gene product), from
GAG, encoding glutamic acid, to GTG, encoding valine
(Figure 1(b)). Codons are numbered according to reference
sequence NM 000508.3.
2.4. Proband Outcome. During 16 years of follow-up after
RTx, there were no episodes of rejection and she was
normotensive. Maximal proteinuria of 0.9 g/day was detected
in 2009 and renal graft function remained good until 4
months before her death; thus, no renal allograft biopsy was
performed. Peptic ulcer due to Helicobacter pylori infection
was diagnosed after an episode of upper gastrointestinal
hemorrhage. Apparent progression of extrarenal amyloid
disease was mainly cardiovascular and hepatic. Repeated
electrocardiography found sinus rhythm, normal intervals,
and no criteria for hypertrophy. Serial echocardiography
showed left atrial enlargement (53mm), severely abnormal
left ventricular hypertrophy (left ventricular mass index
increased from 154 g/m2 in 2006 to 170 g/m2 in 2012, with
a reference range of 43–95 g/m2), mild degenerative valvular
disease, preserved systolic ventricular function, and moder-
ate pulmonary hypertension. These findings were consistent
with cardiac amyloidosis. Hepatic involvement was charac-
terized by mild elevations of gamma-glutamyl transferase
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Table 2: Laboratory data.
Parameter/date 02.14.2006 04.07.2009 08.17.2010 08.14.2012 11.26.2012 12.05.2012
Urea (mg/dL) 69 41 89 136 135 188
Creatinine (mg/dL) 0.80 0.75 1.03 1.22 1.44 4.62
Creatinine clearance (mL/min/1.73m2) 67.9 84.7 68.3 45.9 37.6 9.2
Albumin (g/L) 43.0 45.7
HbA1c (%) 5.9
Uric acid (mg/dL) 6.7 8.9 7.0
Total bilirubin (mg/dL) 0.79 0.60 0.60 0.72 1.13 0.96
AST (U/L) 21 23 23 19 14 22
ALT(U/L) 19 14 20 15 2 12
ALP (U/L) 102 106 134 139 160 170
GGT (U/L) 90 86 88 81 106 65
Sodium (mmol/L) 144 134 136 132 122
Potassium (mmol/L) 4.73 4.17 4.50 4.87 5.73
Chloride (mmol/L) 106 96 101 96 98
Calcium (mmol/L) 2.52 2.56 2.02
Phosphorus (mmol/L) 1.03 1.18 2.09
iPTH (pg/mL) 75 80 103
Total cholesterol (mg/dL) 203 207 196 155
Triglycerides (mg/dL) 127 78 105 111
NT-proBNP (pg/mL) 14 056
CRP (mg/dL) 85.62
Cyclosporine (ng/mL) 80.5 94.7 130.2
Proteinuria (g/24 h) 0.15 0.90 0.51
HbA1c: glycated hemoglobin; AST: aspartate aminotransferase; ALT: alanine aminotransferase; ALP: alkaline phosphatase; GGT: gamma-glutamyl transferase;
iPTH: intact parathyroid hormone; NT-proBNP: N-terminal pro-B-type natriuretic peptide; CRP: C-reactive protein.
and alkaline phosphatase with increasing hepatomegaly; the
liver’s ultrasound diameter reached 22.7 cm in September
2012. At that time, the spleen diameter was 9.4 cm and
there were several calcifications. There was no sign of portal
hypertension. Relevant laboratory data are listed in Table 2.
In August 2012, 4 months before her death, the patient
was hospitalized for Clostridium difficile colitis, which was
successfully treated with metronidazole. One month later,
she was admitted for congestive heart failure with an N-
terminal pro-B-type natriuretic peptide (NT-proBNP) level
of 31 937 pg/mL; this was controlled with diuretic therapy.
In November 2012, she was hospitalized for hyponatremia
associated with effective circulating volume depletion. She
died inDecember 2012 after admission forKlebsiella pneumo-
niae urosepsis, congestive heart failure with NT-proBNP 14
056 pg/mLunresponsive to diuretic therapy, and acute kidney
allograft injury. Autopsy was not performed.
2.5. Kindred. After some years of research, a family tree was
obtained (Figure 1(c)). The research protocol was approved
by the Health Ethics Commission of Centro Hospitalar de
Sa˜o Joa˜o. The mother of the proband (II5) presented with
hypertension aged 67 years. She had a stroke at 76 years
and died from chronic renal failure (CRF) 1 year later. The
father (II6) had hypertension from the age of 55 years,
significant cardiovascular disease (peripheral artery disease,
ischemic cardiopathy), and CRF from 77 years, dying from
pneumonia at 82 years. One paternal aunt (II3) died at 84
years due to hemorrhagic cerebrovascular accident. She had
hypertension from the age of 59 years and CRF from 69 years
and had started hemodialysis at 79 years. One paternal uncle
(II9) had hypertension from the age of 61 years, significant
cardiovascular disease (peripheral artery disease, ischemic
cardiopathy), and CRF from 72 years, dying from uremia
at 78 years. Three first cousins (III7, III8, and III10) had
hypertension (from 57, 55, and 53 years, resp.) and carried
the same amyloidogenic fibrinogen mutation. As patient III5
was homozygous for the FGA p.Glu545Val mutation, all her
offspring are obligatory heterozygotes. This condition was
confirmed by genotyping in all, except IV2, who was abroad,
and IV7, who died at young age. Members IV3 and IV4 had
hypertension from the age of 45 and 43 years, respectively.
3. Discussion
Here, we describe the first AFib amyloidosis patient homozy-
gous for the E526V (p.Glu545Val) mutation and her long
term outcome after isolated RTx. The unexpected etiology
and outcome of this case highlight important aspects of
the clinical management of systemic amyloidosis in general.
Our patient’s prolonged survival without treatment and the
absence of an identifiable monoclonal plasma cell disorder
led us to question the diagnosis ofAL amyloidosis. Retrospec-
tive finding that the amyloid deposits in her kidney biopsy
Case Reports in Nephrology 5
were derived from FGA and the complete concordance
between the presence of the E526V (p.Glu545Val) and the
development of amyloidosis indicated that this mutation was
the cause of the disease in the proband’s family.This approach
ensured family screening.
Immunohistochemical classification of 102 northern Por-
tuguese patients with amyloidosis diagnosed in native kidney
biopsies disclosed 4 (3.9%) cases of AFib, including our
proband.They were all from the same rural geographical area
and belonged to apparently unrelated families [25]. In the
case of our homozygous patient, both parents had CRF and
consanguinity was not possible to prove, but they may share
a common ancestor given the possibility of an endemic focus
of the disease in their region. In this context, homozygosity
proposal was based on DNA sequencing (Figure 1(b)).
Previously reported AFib amyloidosis phenotypes result
from the heterozygous genotype. The effect of homozygosity
on phenotype has been reported for patients with hereditary
transthyretin [14–23] or gelsolin [12, 13] amyloidosis (Table 1),
but this is the first report for AFib amyloidosis. Our patient
presented at a relatively early age and during long term
follow-up apparently developed a heavy disease burden with
multisystem involvement. AfterRTx, serial echocardiography
demonstrated increased wall thickness, despite normoten-
sion and normal graft function, consistent with cardiac
amyloidosis. The main forms of amyloidosis that affect
the heart are light chain and ATTR amyloidosis. Cardiac
involvement of AFib amyloidosis was described in a cohort
of 22 AFib patients [4], 52% had abnormal echocardiographic
findings suggestive of amyloid cardiomyopathy, and 55% had
parasympathetic dysfunction and risk of bradycardia. Coro-
nary atherosclerosis was identified in 68%. In the present
case, cardiac involvement in the setting of established AFib
amyloidosis, with left ventricular hypertrophy on echocar-
diography and a relative low-voltage electrocardiogram, com-
plicated by congestive heart failure refractory to standard
medical therapy, was considered cardiac amyloidosis. Two of
the familymembers developed atherosclerotic cardiovascular
disease with no echocardiographic evidence of cardiac amy-
loidosis. Affected family members developed nephropathy
almost three decades later and five heterozygous carriers
developed hypertension in their forties and fifties. Thus, the
clinical phenotype of our homozygous patient was more
severe (earlier onset of nephropathy, cardiac and hepatic
involvement) than those of heterozygotes in the same family,
consistent with gene dosage effects on the phenotype of AFib
amyloidosis. The follow-up of hypertensive heterozygous
carriers will be helpful in the study of the pathogenesis of
hypertension in AFib amyloidosis.
In systemic amyloidosis, solid organ transplantation has
been used to replace failing organ function [26–29]. Isolated
RTx alone has been performed for ESRF in several patients
with AFib and probably remains appropriate when there is
good evidence that amyloid deposition does not threaten
the function of other vital organs. Gillmore et al. reported
that RTx in AFib is associated with recurrence of amyloid
in the graft with resultant loss of transplanted kidneys
after a median of 6.7 years [3]. CLKT in a patient with
amyloidotic renal failure caused by the FGA p.Glu545Val
mutation was first performed in 1995 [28]. Despite liver
transplantation being the only currently available curative
treatment for AFib, it seems reasonable to propose it for
younger and fitter patients, weighing the high risk of early
perioperative death following CLKT against the elimination
of the risk of recurrent amyloid disease in the allograft
[3, 29]. Transplantation in our patient aimed to replace
her failing organ function, because in 1996 her amyloid
type was unknown; it was 5 years later that we made a
retrospective diagnosis of hereditary fibrinogen amyloido-
sis. Despite isolated RTx, our patient’s outcome was not
unfavourable compared to the results with CLKT [3, 4]. Her
apparent cardiac and hepatic AFib involvement progressed
despite clinical absence of disease recurrence in the allograft.
Mild proteinuria appeared 13 years after transplantation,
but allograft function remained good until 4 months before
the patient’s death. At that time, cardiovascular symptoms
were her principal problem, due to cardiac amyloidosis
suggested by echocardiography. In patients with cardiac AFib
involvement, combined heart-liver, heart-kidney, or heart-
liver-kidney transplantation could be discussed [30, 31], but,
given the high risk in our 67-year-old patient, she received
recommended drug treatment only. She died 16 years after
renal transplantation due to severe heart failure in the context
of sepsis.
4. Conclusions
In conclusion, correct identification of amyloidogenic protein
should always be pursued, even retrospectively, because
it enables the choice of the most appropriate therapy,
avoids unnecessary and potentially harmful treatments, and
ensures family screening. This first report of a homozygous
AFibE526V (p.Glu545Val) amyloidosis expands our knowl-
edge about the phenotype and the outcome of isolated renal
transplantation and may be relevant for understanding the
molecular mechanisms of dominance in hereditary amyloi-
dosis.
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